Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092)
Molecular Case Studies · 2020-02 · 6 (1) · a004549
DOI: 10.1101/mcs.a004549 ↗Kurz gefasst
Fallbericht in der Zeitschrift Molecular Case Studies, online erschienen am 03.02.2020. Verfasst von Leslie G Biesecker und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, US…. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
A 20-yr-old man with Proteus syndrome (PS) and somatic mosaicism of the AKT1 c.49G > A p.(E17K) variant had asymmetric overgrowth of the right frontal and facial bones, asymmetric spinal overgrowth with thoracolumbar scoliosis, dilatation of the inferior vena cava, testicular cystadenoma, bilateral knee deformities, macrodactyly, and apparent intellectual disability. Miransertib (ARQ 092) is an oral, allosteric, selective pan-AKT inhibitor initially developed for cancer therapeutics, now being evaluated for the treatment of PS. After baseline evaluation, the patient started unblinded treatment of 10 mg oral miransertib daily (∼5 mg/m 2 /day), escalated to 30 mg daily (∼15 mg/m 2 /day), and then to 50 mg daily (∼25 mg/m 2 /day) after 3 mo of treatment. Adverse events included dry mouth, one episode of gingivostomatitis, and loose, painful dentition due to preexisting periodontal disease, all of which resolved spontaneously. After 11 mo of treatment, the patient reported improved general well-being, increased mobility of the ankle, spine, and hands, a subjective decrease in size of the right facial bone overgrowth, and reduced areas of cerebriform connective tissue nevi on the soles. Whole-body MRI findings were stable without apparent disease progression. We conclude that 1 yr of treatment with miransertib was beneficial in this case.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
- Hunter Genetics, Hunter-New England Local Health District, New South Wales Department of Health, Waratah, New South Wales 2298, Australia.
- Department of Paediatrics, Western Sydney University School of Medicine, Penrith, New South Wales 2751, Australia.
- Pharmacy, John Hunter Hospital, Hunter-New England Local Health District, New South Wales Department of Health, New South Wales 2310, Australia.
- Medical Imaging, Paediatric Radiology, Hunter-New England Local Health District, New South Wales Department of Health, New South Wales 2310, Australia.
- Arqule Inc, Burlington, Massachusetts 01803, USA.
ORCID-Profile: Matthew Edwards, Brian Schwartz
Zitieren
APA
Biesecker, L. G., Edwards, M., O'Donnell, S., Doherty, P., MacDougall, T., Tith, K., Kazakin, J., & Schwartz, B. (2020). Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092). Molecular Case Studies, 6(1), a004549. https://doi.org/10.1101/mcs.a004549
Vancouver
Biesecker LG, Edwards M, O'Donnell S, Doherty P, MacDougall T, Tith K, et al. Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092). Molecular Case Studies. 2020;6(1):a004549. doi:10.1101/mcs.a004549
BibTeX
@article{Biesecker2020,
author = {Biesecker, Leslie G and Edwards, Matthew and O'Donnell, Sheridan and Doherty, Paula and MacDougall, Thomas and Tith, Kate and Kazakin, Julia and Schwartz, Brian},
title = {Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092)},
journal = {Molecular Case Studies},
year = {2020},
volume = {6},
number = {1},
pages = {a004549},
doi = {10.1101/mcs.a004549}
}
EUVIMED